Literature DB >> 23018478

Pulmonary embolism in pregnancy. Consensus and controversies.

M D Benson1.   

Abstract

Venous thrombotic events (VTE) occur 1-2 per 10,000 pregnancies and remain one of the leading causes of maternal mortality in the developed world. The two largest risk factors are a personal history of VTE and heritable thrombophilias. D-dimer tests for VTE in pregnancy have a high false positive rate and at least some false negatives have been reported. Compression ultrasound should be used to evaluate pregnant women for deep venous thrombosis followed by magnetic resonance imaging of the pelvis for a negative test and strong remaining clinical suspicion. For pulmonary embolism, a chest x-ray should be used to triage the patient to either a ventilation/perfusion study after a normal X-ray or a CT pulmonary angiogram after an abnormal one. Treatment generally consists of low molecular weight heparin through a minimum of six weeks post-partum. Thombolysis might have merit in life-threatening, massive pulmonary embolism. VTE prophylaxis in at-risk populations remains a major area of uncertainty. Mechanical prophylaxis for all women undergoing cesarean, in particular, has a paucity of supportive evidence.

Entities:  

Mesh:

Year:  2012        PMID: 23018478

Source DB:  PubMed          Journal:  Minerva Ginecol        ISSN: 0026-4784


  3 in total

1.  Fluorescence immunoassay of human D-dimer in whole blood.

Authors:  Tae Kyum Kim; Sang Wook Oh; Young Joon Mok; Eui Yul Choi
Journal:  J Clin Lab Anal       Date:  2014-02-27       Impact factor: 2.352

Review 2.  Challenges in interventional radiology: the pregnant patient.

Authors:  Eunice K Moon; Weiping Wang; James S Newman; Maria Del Pilar Bayona-Molano
Journal:  Semin Intervent Radiol       Date:  2013-12       Impact factor: 1.513

3.  Impact of Pregnancy-Related Venous Thromboembolism on Quality of Patients' Lives.

Authors:  Naser Al-Husban; Leena N Alnsour; Zaid El-Adwan; Nada A Saleh; Mazen El-Zibdeh
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.